Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 8/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891519 | 0.83 | MAPK14 (0.55) | MAPK14ALDH1A1CNR2SMN1; SMN2CNR1 | |
| SCHEMBL9893070 | 0.83 | MAPK14 (0.47) | MAPK14RPS6KA2ALDH1A1ADORA2BSMN1; SMN2 | |
| SCHEMBL9891802 | 0.80 | MAPK14 (0.48) | MAPK14RPS6KA2ALDH1A1ADORA2BSMN1; SMN2 | |
| SCHEMBL11738978 | 0.79 | MAPK14 (0.44) | MAPK14RPS6KA2ALDH1A1ADORA2BSMN1; SMN2 | |
| SCHEMBL3660761 | 0.79 | CNR2 (0.42) | MAPK14RPS6KA2CNR2CNR1 | |
| SCHEMBL1464962 | 0.78 | CNR2 (0.47) | MAPK14CNR2CNR1 | |
| SCHEMBL1465876 | 0.77 | CNR2 (0.59) | MAPK14CNR2CNR1 | |
| SCHEMBL14300148 | 0.76 | RPS6KA2 (0.39) | MAPK14RPS6KA2ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL1465041 | 0.75 | RAB9A (0.42) | MAPK14CNR2CNR1RAB9ANPC1 | |
| SCHEMBL1464712 | 0.75 | MMP9 (0.45) | MAPK14CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | MAPK14 1949/4885RPS6KA2 643/4885ALDH1A1 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.